WallStSmart

Amphastar P (AMPH)vsUnited Therapeutics Corporation (UTHR)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

United Therapeutics Corporation generates 327% more annual revenue ($3.19B vs $745.79M). UTHR leads profitability with a 38.6% profit margin vs 13.3%. UTHR appears more attractively valued with a PEG of 2.22. AMPH earns a higher WallStSmart Score of 65/100 (C+).

AMPH

Buy

65

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 6.0Quality: 7.0
Piotroski: 3/9Altman Z: 2.23

UTHR

Buy

55

out of 100

Grade: C

Growth: 4.7Profit: 9.0Value: 5.3Quality: 7.8
Piotroski: 5/9Altman Z: 8.56
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMPHUndervalued (+28.3%)

Margin of Safety

+28.3%

Fair Value

$39.87

Current Price

$29.37

$10.50 discount

UndervaluedFair: $39.87Overvalued
UTHRUndervalued (+2.4%)

Margin of Safety

+2.4%

Fair Value

$487.71

Current Price

$587.88

$100.17 discount

UndervaluedFair: $487.71Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMPH3 strengths · Avg: 8.7/10
EPS GrowthGrowth
135.1%10/10

Earnings expanding 135.1% YoY

P/E RatioValuation
13.1x8/10

Attractively priced relative to earnings

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

UTHR3 strengths · Avg: 9.3/10
Profit MarginProfitability
38.6%10/10

Keeps 39 of every $100 in revenue as profit

Altman Z-ScoreHealth
8.5610/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
29.0%8/10

Strong operational efficiency at 29.0%

Areas to Watch

AMPH3 concerns · Avg: 2.7/10
Market CapQuality
$1.22B3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
2.772/10

Expensive relative to growth rate

UTHR3 concerns · Avg: 3.3/10
PEG RatioValuation
2.224/10

Expensive relative to growth rate

Revenue GrowthGrowth
4.1%4/10

4.1% revenue growth

EPS GrowthGrowth
-20.3%2/10

Earnings declined 20.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : AMPH

The strongest argument for AMPH centers on EPS Growth, P/E Ratio, Price/Book.

Bull Case : UTHR

The strongest argument for UTHR centers on Profit Margin, Altman Z-Score, Operating Margin. Profitability is solid with margins at 38.6% and operating margin at 29.0%.

Bear Case : AMPH

The primary concerns for AMPH are Market Cap, Piotroski F-Score, PEG Ratio.

Bear Case : UTHR

The primary concerns for UTHR are PEG Ratio, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

AMPH carries more volatility with a beta of 0.94 — expect wider price swings.

AMPH is growing revenue faster at 8.2% — sustainability is the question.

UTHR generates stronger free cash flow (126M), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

AMPH scores higher overall (65/100 vs 55/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Amphastar P

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company is headquartered in Rancho Cucamonga, California.

United Therapeutics Corporation

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.

Visit Website →

Want to dig deeper into these stocks?